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Human Bone Morphogenetic Protein-2 (hBMP2) is an osteoinductive agent
physiologically involved in bone remodeling processes. A commercialized recombinant
hBMP2 produced in mammalian cell lines is available in different clinical applications
where bone regeneration is needed, but widespread use has been hindered due to an
unfavorable cost/effective ratio. Protein bodies are very large insoluble protein polymers
that originate within the endoplasmic reticulum by prolamine accumulation during the
cereal seed development. The N-terminal domain of the maize prolamin 27 kD γ-zein
is able to promote protein body biogenesis when fused to other proteins. To produce
high yield of recombinant hBMP2 active domain (ad) in stably transformed tobacco
plants we have fused it to the γ-zein domain. We show that this zein-hBMP2ad fusion
is retained in the endoplasmic reticulum without forming insoluble protein bodies. The
accumulation levels are above 1% of total soluble leaf proteins, indicating that it could
be a rapid and suitable strategy to produce hBMP2ad at affordable costs.
Keywords: bone morphogenetic protein 2, endoplasmic reticulum, protein accumulation, protein bodies, γ-zein,
plant factories
INTRODUCTION
Throughout the adult life, as well as in the healing process following injuries, bone tissue is
subjected to cycles of absorption and formation during the physiological modeling and remodeling.
The former allows to shaping bone structure according to the loading situation, adapting cortical,
and trabecular architecture to the functional needs, while the latter consists of the renewal of bone
composition without changing the bone architecture. However, a massive bone regeneration may
be required in pathological conditions such as in the presence of extensive bony defects caused by
trauma, bone cancer, infection and necrosis, or because the remodeling process is compromised,
such as in osteoporosis (Giannoudis et al., 2005).
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The availability of Bone Morphogenetic Proteins (hBMPs),
the osteoinductive agents in bone, as an adjunct to surgical
procedures involving bone reconstruction, might reduce or avoid
the need for complex and demanding surgeries, preventingmajor
costs, and morbidity related to autograft harvesting (Garrison
et al., 2007; Lo et al., 2012). Among the 20 members of hBMPs,
which belong to TGF beta superfamily, only hBMP-2, -4, -6, -
7, -9, and -14 have shown promising osteoinductive properties
in different injuries (e.g., long bone fracture non-unions, spinal
fusion, and maxillofacial bone defects; Even et al., 2012; Lo
et al., 2012; Carreira et al., 2014). hBMP2 and hBMP7 are
the most characterized factors and are able to strongly induce
osteoblast differentiation in different tissues (Marie et al., 2002).
In 2007, an extensive survey on the cost-effectiveness of the
use of recombinant hBMPs (rhBMPs) in orthopedy concluded
that there is lack of evidence about the clinical effectiveness
and that their use would not be cost-effective unless the price
is significantly reduced, except for severe cases (Garrison et al.,
2007). Over the past 10 years, evidence about the clinical
efficacy of rhBMP2 has been provided by sponsored clinical
studies (Burks and Nair, 2010; Kim et al., 2015). Based on
preliminary clinical results in oral, maxillofacial and orthopedic
surgeries, rhBMP2 is as effective as the conventional grafting
according to clinical and histomorphometric parameters, and
in some cases it may accelerate bone healing (Kelly et al.,
2015; Lin et al., 2015; Poon et al., 2016). Moreover, rhBMP2
may decrease morbidity and improve other patient-associated
outcomes, with no signs of rejection or infection (Alt et al., 2015;
Lin et al., 2015; Poon et al., 2016). On the other hand, while
complications and adverse events were rarely reported using
rhBMPs for their specific clinical indications, pitfalls have been
observed with off-label use of rhBMP2, leading to a number
of adverse effects (Poon et al., 2016). Finally, some authors
have still expressed concern regarding the actual effectiveness
and safety of rhBMPs, highlighting the risk of potential serious
complications, as reported by non-sponsored studies (Even et al.,
2012).
Despite the promising clinical results and the improvements
in the production procedures of recent years, the widespread
therapeutic use of rhBMPs has been hindered until now, both
because of the FDA limitations on their applications, and the
failure to obtain high amount of pure and biologically active
protein at an affordable price (Harada et al., 2012; Carreira et al.,
2014).
hBMP2 is synthesized as an inactive dimer that undergoes
major posttranslational modifications to become biologically
active. Each of the BMP-2 monomers (405 AA) contains a
cysteine-knot which is based on six cysteine residues (C296,
C325, C329, C361, C393, C395) forming three intra-chain
disulfide bridges (Scheufler et al., 1999). The cystine-knot scaffold
confers rigidity to the structure and it is necessary to stabilize
the whole protein. The hBMP2 dimers are formed by a single
inter-chain disulfide bond which engages the unpaired C360 of
each monomer (Scheufler et al., 1999). The key post-translational
modification is the endoproteolytic cleavage by proprotein
convertase downstream the R282 in the KREKR consensus site
that releases the mature homodimeric hBMP2 active domain
(Heng et al., 2010).
Several attempts to express recombinant active hBMPs
in different heterologous systems (such as Escherichia coli,
P. pastoris, Baculovirus/insect cells, and mammalian cells) have
been made (Colin et al., 2008). However, the production has
encountered difficulties, especially due to the impairment of
protein folding, different grade or absence of post-translational
modifications and low protein stability (Hazama et al., 1995;
Pulkki et al., 2011; Park et al., 2014.). In 2002 the first
recombinant hBMP2 obtained fromCHO cell lines was approved
by the FDA (FDA approval number: P000054). Although
mammalian cells are disadvantageous in terms of complexity
and cost, the recombinant hBMP2 (rhBMP-2) and rhBMP-7 by
Medtronic are so far the only ones to be marketed.
During the last two decades, plants have emerged as one of
the most promising general production platforms for biologics,
and nowadays plant-based expression systems are accepted as
robust, scalable and cost-efficient platforms for the production
of recombinant proteins of pharmaceutical interest, including
antibodies, blood substitutes, vaccines, and growth factors (Ma
et al., 2003; Fischer et al., 2004; Stoger et al., 2005; Melnik and
Stoger, 2013; Sack et al., 2015).
A previous attempt to produce rhBMP2 in tobacco plants
has been made (Suo et al., 2006). The level of accumulation of
a recombinant protein in transgenic plants is protein specific
and strongly influenced by the subcellular compartment of
destination (Vitale and Pedrazzini, 2005); thus, search for the best
subcellular compartment for the protein of interest represents
a major issue in the effort to maximize production (Vitale and
Pedrazzini, 2005; Hofbauer and Stoger, 2013). Several targeting
strategies have been developed to improve protein accumulation
in plant cells and one of the most promising is to exploit the
seed storage protein determinants deputed to the formation of
large oligomers that accumulate in the endoplasmic reticulum of
maize endosperm, resulting in protein body (PB) biogenesis. The
27 kD γ-zein (hereafter zein) is a maize storage protein belonging
to the prolamin class and is able to induce PB biogenesis even
when expressed in vegetative tissues of transgenic plants (Shewry
et al., 1995; Vitale and Ceriotti, 2004). Its N-terminal domain,
characterized by eight repeats of the hexapeptide VHLPPP and
seven cysteine residues is necessary for retention and deposition
into the ER (Geli et al., 1994; Mainieri et al., 2014). The cysteine
residues form inter-chain disulphide bonds, leading to assembly
into the very large PBs. These polymers are therefore insoluble
unless treated with reducing agents (Mainieri et al., 2004, 2014;
Pompa and Vitale, 2006). This domain has been used to allow
accumulation of recombinant fusion proteins both in transgenic
plants and in mammalian cells (Mainieri et al., 2004; Llop-Tous
et al., 2011).
In order to investigate new cost-effective approaches to
express the hBMP2 in tobacco transgenic plants, we produced
a chimeric protein (named zein-hBMP2ad), consisting of the
C-terminal active domain of hBMP2 fused to the N-terminal
domain of 27 kD γ-zein. We show that the prolamin domain
promotes higher accumulation level of hBMP2ad compared
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to the native hBMP2 (hBMP2nat). zein-hBMP2ad assembly,
post-translational modifications and ability to induced PB
biogenesis were analyzed.
MATERIALS AND METHODS
Plasmid Construction
The constructs used in this study are shown in Figure 1, and were
prepared according to standardmolecular techniques (Sambrook
et al., 1989).
A single chimeric construct including the N-Terminal of
27 kDa γ-zein, a DNA linker, a Thrombin cleavage site, the
complete coding sequence of human BMP2 and a FLAG epitope
was purchased fromGeneCust (GeneCust Europe, Laboratoire de
Biotechnologie du Luxembourg S.A.) in a pUC57 vector in order
to obtain the two zein-hBMP2ad and hBMP2nat constructs with
specific subcloning experiments.
The chimeric gene zein-hBMP2ad was obtained by double
digestion with XbaI and PstI and the insertion of the excised
fragment in a pDHA vector. To reach the final sequence this
plasmid was digested with AflII in order to excise the signal
peptide and the pro-peptide of hBMP2. The resulting construct
was used for transient expression in tobacco protoplasts. Full-
length hBMP2 (hBMP2nat) was obtained by digestion with SalI
and PstI. The fragment was then subcloned in a pDHA vector and
used for transient expression in tobacco protoplasts.
For stable plant transformation, the EcoRI fragments excised
from the two pDHA plasmids, containing the expression
cassettes, were subcloned into EcoRI-linearized pGreenII 0179
(http://www.pgreen.ac.uk, John Innes Centre, Norwich, Norfolk,
UK) that carries the hygromycin selectable marker gene. These
constructs, called pGreen-ER and pGreen-N, were used to
transform A. tumefaciens strain GV3101 by electroporation, as
described by Shen and Forde (1989).
Antibodies and Recombinant Protein
Rabbit polyclonal anti-FLAG (1:2000 Sigma Aldrich, St. Louis,
MO, USA); rabbit polyclonal anti-tobacco BiP (1:10,000
dilution, Pedrazzini et al., 1997); rabbit polyclonal anti-
endoplasmin/GRP94 (1:1000 dilution; Klein et al., 2006);
goat anti-rabbit IgG-peroxidase conjugate (1:16,000, Pierce
Biotechnology (Rockford, IL, USA). FLAG-Bap recombinant
fusion protein (Sigma Aldrich, St. Louis, MO, USA).
Plant Material
Nicotiana tabacum plants (cv. Petit Havana SR1) as well as
transgenics were cultured in sterile conditions on Murashige and
Skoog (MS) basal salt medium (Duchefa Biochemie, Haarlem, the
Netherlands) containing 0.8% plant agar (Duchefa Biochemie) or
in soil in a growth room at 25◦C with a 16-h/8-h light/dark cycle.
A. tumefaciens-Mediated Transformation
Young tobacco leaves were excised from axenically grown wild-
type plants and cut into about 1 cm2 leaf discs. The discs were
placed for 5min in a culture of A. tumefaciens carrying the
plasmid of interest, and then incubated at 25◦C in 16 h of light on
MS salts medium (Duchefa Biochemie), containing 3% sucrose
and 0.8% phyto agar, underside down. After 2 days, the leaf discs
were transferred to a shoot generation medium (1/2MS salts
supplemented with 30 g/l sucrose, 0.1mg/l α-naphthalene acetic
acid, 0.1mg/l 6-benzylaminopurine, 50µg/ml hygromycin,
100µg/ml carbenicillin and 250µg/ml cefotaxime, and 0.8%
phyto agar) in order to promote callus growth, select transformed
plants and to prevent further growth of Agrobacterium.
Elongated shoots were excised from calli and transferred on to
1/2 MS agar supplemented with 0.1mg/L indole-3-acetic acid,
50mg/L hygromycin and 100mg/L carbenicillin in order to
promote roots formation. Transformed plants were grown at
25◦C in 16 h of light in axenic conditions without antibiotics and
propagated every 5–6 weeks.
Transient Expression Tobacco Protoplasts
and Analysis of Proteins
Protoplasts were isolated from tobacco leaves and subjected
to polyethylene glycol-mediated transfection, as described by
Pedrazzini et al. (1997). Forty micrograms of pDHA plasmid
without insert (as a negative control) or with inserted
recombinant coding sequences (pDHA-zein-hBMP2 and pDHA-
hBMP2nat) were used in each transfection at a concentration
of 106 cells/mL. Protoplasts were then allowed to recover
overnight in the dark at 25◦C in K3 medium (Gamborg’s B5
basal media with minimal organics supplemented with 400mM
sucrose, 1.5M xylose, 3mMNH4NO3, 1 mg/l α-naphtalenacetic
acid, 1mg/l 6-benzylaminopurine and 5mM CaCl2) before
performing protein extraction.
Protoplast homogenization was performed by adding to
frozen samples two volumes of ice-cold homogenization buffer
(150mMTris-Cl, 150mMNaCl, 1.5mM EDTA, and 1.5% Triton
X-100, pH 7.5) supplemented with Complete R© protease inhibitor
cocktail (Roche, Basel). For protein extraction performed in
reducing condition, the buffer was supplemented also with 4% 2-
mercaptoethanol. Equal amounts of each sample were denatured
with Laemmli buffer, loaded on to 15% SDS-PAGE together
with the Protein Molecular Weight Marker mixture (Fermentas,
Vilnius, Lithuania) and electrotransferred to a polyvinylidene
difluoride (PVDF) membrane (Protran Nitrocellulose Transfer
Membranes, Perkin Elmer). Blots were probed with anti-
FLAG mAbs and proteins were detected using a horseradish
peroxidase-conjugated anti-rabbit secondary antibody (Pierce
Biotechnology, Rockford, IL), followed by chemiluminescence
with Super-Signal R© West Pico Chemiluminescent Substrate
(Pierce Biotechnology, Rockford, IL). Detection of bands was
performed with the ChemiDoc MP Imaging Systems (Bio-Rad,
Hercules, CA).
Protein Extraction from Tobacco Leaves
and Western Blot Analysis
Screening of tobacco transgenic lines expressing zein-hBMP2ad
or hBMP2nat was performed by direct homogenization of leaves
(0.1mg, fresh weight) in Laemmli buffer at 95◦C (ratio 7:1).
Twenty-five microliters of leaf homogenate from each sample
(corresponding to 12.5µg of total leaf proteins) were loaded
on SDS-PAGE, followed by protein blot analysis with anti-Flag
antiserum.
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FIGURE 1 | Schematic representation of hBMP2nat, 27 kD γ-zein, and zein-hBMP2ad fusion. Dark gray box: human BMP2 active domain (ad); light gray box:
27 kD γ-zein N-terminal domain; hatched box: thrombin consensus cleavage site; black triangles: cysteine residues involved in interchain-disulfide bridges.
N-glycosylated sites in hBMP2 are indicated. Intrachain disulphide bridges in hBMP2ad and in the C-terminal region of 27 kD γ-zein are indicated. SP: Signal Peptide.
Expected Molecular Mass: hBMP2nat, 45.8 kD; hBMP2ad, 14 kD; 27 kD γzein, 23.7 kD; zein-hBMP2ad, 27.4 kD.
For the extraction of total proteins, young (5–7 cm long)
leaves of transgenic tobacco were homogenized in an ice-
cold mortar with seven volumes of homogenization buffer
(200mM NaCl, 1mM EDTA, 0.2% Triton X-100, 100mM Tris-
Cl, pH 7.8) supplemented with Complete R© protease inhibitor
cocktail (Roche, Basel). For protein extraction performed in
reducing condition, the buffer was supplemented also with 4%
2-mercaptoethanol. The homogenate was then centrifuged at
1500 g for 10min at 4◦C and the protein concentration of the
supernatants was determined using the Bio-Rad protein assay
(Bio-Rad, Hercules, CA, USA). Supernatant and, in some cases,
pellet were then analyzed by protein blot. Equal amounts of total
protein from each sample were denatured with Laemmli buffer
and then processed as described above for protoplasts protein
extracts. Densitometric analysis of bands was performed with
Image Lab software (Version 4.1, Bio-rad).
Endoglycosidase H Treatment
Protein samples extracted either from transgenic leaves or
from transfected protoplasts were incubated in Glycoprotein
Denaturing Buffer (0.5% (w/v) SDS, 40mM) for 10min at 100◦C.
Samples were brought to a volume of at least 20µl by adding
of 10x G5 Reaction Buffer (50mM sodium citrate pH 5.5) and
divided in two equal aliquots. One of them was treated with
2000 Units of Endo H enzyme (New England Biolabs, Beverly,
MA, USA), the other one with an equal volume of water. After
2 h incubation at 37◦C the samples were supplemented with
Laemmli denaturation buffer and analyzed by either SDS-PAGE
and protein blotting.
Velocity Centrifugation on Sucrose
Gradient
Young leaves of transgenic and control plants were homogenized
using the above described homogenization buffer in absence of
4% 2-mercaptoethanol. The homogenate was loaded on a linear
5–25% (w/v) sucrose gradient made in 150mM NaCl, 1mM
EDTA, 0.1% Triton X-100, 50mM Tris-Cl, pH 7.5. An additional
gradient was loaded with amixture of proteinmarkers containing
200µg each of cytochrome C (12.4 kDa), ovalbumin (43 kDa),
BSA (66 kDa), aldolase (161 kDa), and catalase (232 kDa). After
centrifugation at 200,000 g for 20 h at 4◦C in a Beckman
SW40 rotor, fractions of about 650µl were collected. An equal
aliquot of each fraction was analyzed by SDS-PAGE and protein
blot.
Subcellular Fractionation on Isopycnic
Sucrose Gradients
Young leaves of transgenic and wild type plants were
homogenized in an ice-cold mortar with a 7:1 (v/w) ratio
of homogenization buffer (100mM Tris-Cl pH 7.8, 10mM
KCl, 12% sucrose (w/w), and Complete R© protease inhibitor
cocktail) containing either 1mM EDTA or 10mM MgCl2.
Six hundred microliters of each sample were loaded on the
top of 12mL of liner sucrose gradient [100mM Tris-Cl pH
7.8, 10mM KCl, 16–65% sucrose (w/w)] and centrifuged at
150,000 g for 2 h at 4◦C in a Beckman SW40 rotor (Beckman,
Fullerton, CA, USA). After centrifugation, 20 fractions of
about 600µL were collected and an equal amount of each
fraction was denatured and analyzed by SDS-PAGE and protein
blot.
Thrombin Cleavage
Twenty-five micrograms of leaf total proteins, extracted in
reducing condition from transgenic and wild type plants, were
incubated with 10 units of thrombin (Amersham Biosciences,
Piscataway, NJ, USA) or PBS (as control) at 22◦C for 20 h, under
gentle agitation. After digestion, samples were denatured and
analyzed by SDS-PAGE and protein blot.
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RESULTS
The fusion construct zein-hBMP2ad (Figure 1) contains the
first 112 amino acids of 27 kD γ-zein, including its 19aa signal
peptide, (Mainieri et al., 2004; de Virgilio et al., 2008; Virgili-
López et al., 2013) followed by the C-terminal, active domain of
hBMP2 (ad, 114 amino acids). The zein portion includes six out
of the seven unpaired cysteine residues as well as the VHLPPP
amphipathic heptapeptide. This is the same domain used in
Mainieri et al. (2004) and it leads to the assembly of zeolin into
PBs. A short flexible linker and a thrombin cleavage site were
inserted between the fusion partners, to favor the independent
folding of the twomoieties and hBMP2ad purification (Figure 1).
The full length native hBMP2 (hBMP2nat) pre-pro-sequence
(which includes the hBMP2 signal peptide and the following
pre-pro peptide) was also expressed, as a control. A C-terminal
FLAG epitope was added to both recombinant constructs, to
allow immunodetection (Figure 1).
zein-hBMP2ad and hBMP2nat Are Soluble
and Are Not Secreted in Tobacco
Mesophyll Protoplasts
The two constructs were transiently expressed in tobacco
mesophyll protoplasts under the control of an enhanced
cauliflower mosaic virus (CaMV) 35S promoter. The pDHA
empty vector was used as further control (Co). The influence
of disulphide bonds on solubility can be tested by protoplasts
homogenization with buffer containing or not the reducing
agent 2-mercaptoethanol (2-ME), followed by centrifugation to
separate soluble and insoluble proteins. Solubilized proteins were
then denatured in the presence of SDS and 2-ME and analyzed
by SDS-PAGE in reducing conditions followed by protein blot
with anti-Flag antibodies. When homogenization was performed
in the absence of 2-ME, zein-hBMP2ad is recovered mainly
as soluble form of about 55 kD that could represent dimers
particularly difficult to denature (Figure 2A, lane 3). Higher
molecular mass forms were also detected, as well as a polypeptide
of about 37 kD. When homogenization was performed in the
presence of 2-ME, the 37 kD form was by far the major one
detected, indicating that it represents the monomeric form,
which remains strongly assembled into dimers and further
polymers when the reducing agent is not present at the time of
homogenization (Figure 2A, lane 4). An 18 kD polypeptide was
also detected, probably derived by proteolytic cleavage occurring
in the C-terminal region.
hBMP2nat migrated as a polypeptide of 45 kD, as expected,
but it accumulated at much lower levels than the zein fusion
and was soluble only in the presence of 2-ME (Figure 2A, lanes
5, 6). Neither zein-hBMP2ad nor hBMP2nat were detectable
in the protoplast incubation medium (Figure 2A, lanes 7–
12), strongly suggesting that the two proteins were not
secreted.
To verify whether a proportion of protein remains insoluble
even when homogenized in the presence of 2-ME, after
homogenization in oxidizing or reducing conditions samples
where centrifuged and both soluble (S) and insoluble (I)
fractions were denatured and analyzed by SDS-PAGE and
protein blot (Figure 2B). Only a small amount of zein-hBMP2ad
was insoluble, both in the presence and absence of 2-ME
(Figure 2B, lanes 6, 8), confirming that this recombinant protein
is almost completely soluble in aqueous buffer. A higher
proportion of hBMP2nat (about 20%) remained insoluble after
homogenization with the reducing agent (Figure 2B, compare
lanes 11 and 12). When homogenization was performed without
2-ME, hBMP2nat was not recovered, neither in the soluble
fraction nor as an insoluble precipitate (Figure 2B, lanes 9–10),
indicating that tissue homogenization without the reducing
agent could lead to the precipitation of insoluble aggregates of
hBMP2nat that cannot be further denatured.
In Transgenic Plants, zein-hBMP2ad Is
Retained in the ER Mainly as Soluble
Dimers and Accumulates at Higher Levels
Compared to hBMP2nat
Since both zein-hBMP2ad and hBMP2nat accumulated during
transient expression, albeit at different levels, we produced
tobacco transgenic plants expressing the two constructs under
the CaMV35S promoter. Leaf extract from several hygromycin
resistant putative transgenic lines grown in axenic conditions
for 4–6 weeks were analyzed by protein blot with anti-Flag
antiserum. Accumulation of the recombinant proteins was
variable, as it nearly always happens when different transgenic
plants are analyzed; however, zein-hBMP2ad showed a clear
tendency to accumulate at much higher levels than hBMP2nat
(Figure 3, compare upper and bottom panels, and notice that the
hBMP2nat protein blot was exposed for a 15 times longer time
than the zein-hBMP2ad one).
The solubility grade of hBMP2nat and zein-hBMP2ad in
transgenic plants was tested by homogenization in either
oxidizing or reducing conditions. The banding pattern as well
as the solubility of zein-hBMP2ad were very similar to those
obtained upon transient expression (Figure 4B, lanes 3, 4, and
compare with lanes 3 and 4 in Figure 2A), with most of the
protein soluble in the absence of 2-ME. When hBMP2nat leaf
homogenization was performed in the absence of reducing
agent, a polypeptide of the expected 45 kD molecular mass
was detected (Figure 4A, lane 3), as well as a larger form
around 55 kD that could indicate heterogeneous N-glycosylation
(Hang et al., 2014, and see below). However, in the presence
of 2-ME, instead of these two main polypeptides several other
forms were detected (Figure 4A, lane 4), that became also
visible in transient expression by longer exposure of the blot in
Figure 2A (see Figure S1, lanes 5, 6), suggesting the presence
of intrachain disulfide bonds and/or partial proteolysis. Two
of these polypeptides were also observed in extracts from
untransformed plants (Figure 4A, lane 2), and represented
endogenous tobacco proteins, visible because of the relatively
high amount of total protein loaded to clearly visualize the
hBMP2nat polypeptides. Notice that in Figure 4 one tenth of the
total amount of leaf protein was analyzed in Figure 4B compared
to Figure 4A, because of the higher amount of zein-hBMP2ad
accumulation with respect to hBMP2nat; for this reason the
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FIGURE 2 | hBMP2nat and zein-hBMP2ad are soluble in transiently transfected protoplasts and are not secreted. (A,B) Tobacco leaf protoplasts were
transiently transfected with plasmid encoding hBMP2nat (lanes 5–6, 11–12), zein-hBMP2ad (lanes 3–4, 9–10), or empty plasmid lanes (1–2, 7–8) and incubated for
24 h. (A) Protoplasts or incubation media were homogenized in the presence (+) or absence (−) of 2-ME. Aliquots corresponding to 20.000 protoplasts (cells) or the
corresponding incubation medium (medium) were analyzed by SDS-PAGE in reducing conditions, followed by protein blot with anti-Flag antiserum. (B) Aliquots
corresponding to 16.500 protoplasts were homogenized in the presence (+) or absence (−) of 2-ME. After centrifugation, soluble (S) material and insoluble precipitate
(I) were analyzed by SDS-PAGE in reducing conditions, followed by protein blot with anti-Flag antiserum. Asterisk: 18 kD fragment of hBMP2ad. Numbers on the left
indicate the positions of molecular mass markers, in kD.
FIGURE 3 | zein-hBMP2ad accumulates to higher levels than hBMP2nat in transgenic plants. Leaves (0.5 g, fresh weight) from independent transgenic
tobacco plants expressing hBMP2nat (upper panel, lines 1–19), zein-hBMP2ad (lower panel, lines 1–11, 21–29) or untransformed plants (wt), were homogenized in
Laemmli buffer at 95◦C (ratio 7:1). Twenty-five microliters of leaf homogenate from each sample (corresponding to 12.5µg of total leaf proteins) were subjected to
SDS-PAGE, followed by protein blot analysis with anti-Flag antiserum. Protein blot exposure time: hBMP2nat, 15min; zein-hBMP2, 1min. Numbers on the left indicate
the position and size (in kDa) of molecular mass markers.
endogenous tobacco polypeptides recognized by the anti-Flag
antiserum were not visible in Figure 4B.
We reasoned that the zein fusion could be more promising for
the production of recombinant hBMP2ad because of its higher
accumulation levels compared with those of the native osteogenic
factor. We therefore focussed on zein-hBMP2ad for subsequent
experiments.
Previously published data showed that, in transgenic plants,
full-length γ-zein or protein fusions containing its N-terminal
domain were insoluble in the absence of reducing agent and
were formed by very large disulfide-bonded polymers that
migrated at the bottom of the tube under velocity centrifugation
analysis (Bellucci et al., 2000; Mainieri et al., 2004; Torrent
et al., 2009a; Virgili-López et al., 2013). Conversely, our
results showed that zein-hBMP2ad was similarly soluble in
oxidizing and reducing conditions. We therefore investigated
its polymerization grade. Total leaf homogenate from zein-
hBMP2ad line #7 (see Figure 3, bottom panel) was extracted
in the absence of 2-ME and fractionated by velocity sucrose
(5–25% w/v) gradient ultracentrifugation. Equal proportions
of each fraction and of the pellet at the bottom of the tube
(solubilized by SDS-PAGE denaturation buffer) were analyzed by
protein blot with anti-Flag antiserum (Figure 5). zein-hBMP2ad
migrated both as dimers (Figure 5, asterisk) and as multimers
that fractionated at progressively distant positions along the
gradient until the bottom of the tube, indicating the formation
of very large polymers that were nevertheless still soluble. Only
a very small proportion ended up at the bottom of the tube;
this pellet could contain insoluble polymers. As the size of the
polymers increased and exceeded the 231 kD marker, these could
no longer be disassembled by the SDS-PAGE and migrated
progressively more slowly. The larger ones actually remained at
the interface between the stacking and separating gels (Figure 5,
arrow).
The intracellular localization of zein-hBMP2ad was
investigated by subcellular fractionation on isopycnic sucrose
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FIGURE 4 | Both hBMP2nat and zein-hBMP2ad are soluble in tobacco
transgenic plants. Thirty micrograms of total leaf proteins from wild type (wt,
A, lanes 1–2) and hBMP2nat line #3 (A, lanes 3–4) plants or 3µg of total leaf
proteins from wild type (wt, B, lanes 1–2) and zein-hBMP2ad line #7 (B, lanes
3–4) plants, were extracted in the absence (−) or presence (+) of 2-ME and
analyzed by SDS-PAGE and protein blot with anti-Flag antiserum. Asterisk: 18
kD hBMP2ad fragment. Numbers on the left indicate the positions of
molecular mass markers, in kD.
density gradient. Because the binding of ribosomes to the
ER membrane is dependent on Mg2+, the chelation of
this cation with ethylenediaminetetraacetic acid (EDTA)
disengages the ribosomes from the membrane, determining a
density shift of the ER-derived microsomes, and not of other
compartments, to lighter fractions of the gradient. Leaves from
zein-hBMP2ad (line #23) were homogenized in the absence of
detergent and in the presence of sucrose to maintain organelle
integrity. The homogenate was loaded on two 16–65% (W/W)
sucrose gradients containing Mg2+ or EDTA and subjected to
centrifugation. Equal amount of each fraction were analyzed
by SDS-PAGE followed by protein blot with either anti-Flag
serum or sera against the ER markers BiP and endoplasmin
(Grp94). In the presence of Mg2+, zein-hBMP2ad was mainly
detected in four fractions with a peak around a density of
1.18–1.19 mg/mL, where the ER marker BiP and Grp94
also peaked (Figure 6, panels on the left). The presence of
EDTA caused a shift of both zein-hBMP2ad, BiP and Grp94
to lower density fractions (peaks around 1.16–1.17mg/mL),
coherent with the density shift of the ER due to ribosome
release (Figure 6, panels on the right). The ER marker BiP
and, in minor proportion Grp94 and zein-hBMP2ad, were also
present at the top of the gradient, as observed previously in
similar experiments (Pedrazzini et al., 1997; Mainieri et al.,
2004), possibly reflecting partial release from the ER lumen on
homogenization.
FIGURE 5 | zein-hBMP2ad assembles both in dimers and in
progressively larger multimers. Eight hundred micrograms of total leaf
proteins from zein-hBMP2ad line #7 were extracted in the absence of 2-ME
and fractionated by velocity sucrose (5–25% w/v) gradient centrifugation. Equal
volume of fractions and the pellet at the bottom of the tube were analyzed by
protein blot with anti-Flag antiserum. Asterisk indicates zein-hBMP2ad dimers.
Arrow indicates the interface between stacking and separating gels. P: pellet
at the bottom of the tube. Numbers on the top indicate the position along the
gradient and the molecular mass (kD) of velocity centrifugation markers.
Numbers on the left indicate the positions of molecular mass markers, in kD.
Taken together, our results indicate that the 27 kD γ-zein
N-terminal domain is sufficient to retain zein-hBMP2ad in
the ER, but it does not allow the hyper-polymerization and
insolubility that are typical of protein bodies formed by zein in
maize endosperm and zeolin in transgenic tobacco.
zein-hBMP2ad is Glycosylated in Tobacco
Transgenic Plants
Native hBMP2 contains five putative N-glycosylation sequons:
four of them occur within the protein prosegment domain
(positions N135, N163, N164, N200), and one in the active
domain (position N338). It has been recently demonstrated that
in both CHO and HEK293T cells, the positions N135, N200,
and N338 are actually glycosylated (see Figure 1), suggesting
that the N-glycosylation status of hBMP2 is independent of cell
types and species (Hang et al., 2014). Moreover, the three N-
glycans are sensitive to peptide-N-glycanase F (PNGase F, which
removes both high-mannose and Golgi-modified, complex type
N-glycans) and Endoglycosidase H (Endo H, which removes
only high-mannose glycans), indicating that they are of the high-
mannose type. The N-terminal region of 27 kD γ-zein does not
contain N-glycosylation sites.
To asses whether the N-glycosylation at position N338 of
the active domain was maintained in zein-hBMP2ad transgenic
plants, total leaf proteins form line #7 were extracted in the
presence of 2-ME and incubated with or without Endo H.
Treatment with the endoglycosidase caused an electrophoresis
mobility shift, consistent with the removal of one high-mannose
N-linked glycan (Figure 7, compare lane 1 and 2). Upon long
exposure of the blot, the 18 kD fragment was detectable and
was also sensitive to Endo H digestion (Figure 7, bottom
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FIGURE 6 | zein-hBMP2ad cofractionates with the ER. Hundred milligrams of fresh leaves from zein-hBMP2ad line #23 were homogenized in sucrose buffer, in
the absence of detergent. The homogenates were fractionated by centrifugation on isopycnic sucrose gradient (16–65% w/w) in the presence of MgCl2 (left panels) or
EDTA (right panels). Collected fractions were analyzed by SDS-PAGE followed by immunoblotting with anti-Flag antiserum (upper panels) or with a mix of anti-BiP and
anti-Grp94 antisera (bottom panels). T, total extract; P, pellet at the bottom of the tube. Numbers at top indicate the density (g/ml) of sucrose. Numbers at left indicate
the position of molecular mass markers, in kD.
panel, compare lane 1 and 2). Taken together, the results
indicate that in transgenic plants the N338 position of hBMP2ad
is N-glycosylated and the 18 kD fragment is most probably
the active domain that has been cleaved from the γ-zein
moiety.
The hBMP2 Active Domain Can Be
Efficiently Recovered by Thrombin
Cleavage
It has been previously observed that the accumulation levels of
recombinant proteins in transgenic plants could depend on leaf
age and size, with younger leaves showing better performance
than the older ones (McCabe et al., 2008; Kolotilin et al., 2013).
The size and position of leaves along the stem identify their
age: older and larger leaves are positioned below newer ones. To
analyze zein-hBMP2ad accumulation in relationship to leaf age,
total proteins were extracted without 2-ME from leaves (line #7,
see Figure 3) with different size (from the bottom to the apex).
Younger leaves accumulate higher amounts of zein-hBMP2ad
permg of total protein (Figure S2, lanes 2, 9). In the light of
these results, 3–4 cm long leaves from young plants were used to
quantify the hBMP2ad produced by tobacco plants.
A preliminary quantification of the full-length zein-hBMP2ad
was performed by densitometric analysis of the bands by
comparing progressive dilutions of total leaf proteins from line
#23 (see Figure 3), extracted in the presence or absence of
2-ME (Figure 8, upper and lower panels, respectively) with
known amounts of the commercial standard protein Flag–BAP,
(Figure 8, lanes on the left). The results indicated that full-length
zein-hBMP2ad could represents about 1.1 and 1.25% of total
soluble proteins extracted with or without 2-ME, respectively.
Densitometric quantification of zein-hBMP2ad full-length from
other independent lines showed that the accumulation levels
reached the 1.75 and 2.25% in plants #7 and #27, respectively
(Figure S3), indicating a certain grade of variability (see
Figure S2).
FIGURE 7 | zein-hBMP2ad is N-glycosylated. Eight micrograms of total
leaf proteins from zein-hBMP2ad line #7 or from wt plants, extracted in the
presence of 2-ME, were incubated with Endo H (+) or without enzyme (−) as
control and analyzed by SDS-PAGE and protein blot with anti-Flag antiserum.
Bottom panel: longer exposure of the 14–18 kD portion of the blot. Numbers
at left indicate the position of molecular mass markers, in kD.
To investigate the accessibility of the thrombin cleavage
site to the protease and to quantify the yield of hBMP2ad,
total leaf proteins were extracted in reducing conditions from
wild-type or two different zein-hBMP2ad plants (#7 and #27)
and subjected to digestion with thrombin or incubated in
the absence of the enzyme for 20 h. Samples were analyzed
by SDS-PAGE and protein blot with anti-Flag antiserum
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FIGURE 8 | Quantification of zein-hBMP2ad expressed in tobacco
plants. Sequential dilutions of total leaf proteins (from 0.5 to 4µg) from
zein-hBMP2ad line #23 extracted in the presence (+2-ME) or in the absence
(−2-ME) of 2-mercaptoethanol were analyzed by protein blot in comparison
with known amounts of the commercial standard protein Flag–BAP (lanes on
the left). Empty circle: zein-hBMP2ad monomers; asterisk: zein-hBMP2ad
dimers. Numbers at left indicate the position of molecular mass markers, in kD.
(Figure 9, lanes 6–11). Under mock treatment, zein-hBMP2ad
monomers, dimers and polymers are observed (Figure 9, lanes
8, 10); the 18 kD proteolytic fragment was also present
(Figure 9, lanes 8, 10, asterisks). The fusion protein zein-
hBMP2ad was efficiently cleaved by thrombin and the hBMP2ad
portion was mostly released as a 20 kD fragment (Figure 9,
lanes 9, 11, empty circles), corresponding to the expected
molecular mass of the N-glycosylated active domain. The exact
efficiency of cleavage is not easy to establish, because of the
smeared electrophoretic pattern of the undigested protein, but
clearly the vast majority of polypeptides have been successfully
cleaved. The 18 kD fragment did not change electrophoretic
mobility upon thrombin treatment, indicating that its N-
terminus is downstream the thrombin cleavage site and upstream
the N-glycosylation site (Figure 9, asterisks, compare lanes
8–9 and 10–11). Quantification of the unpurified hBMP2ad
fragment performed by comparison with known amounts of the
commercial standard protein Flag–BAP (Figure 9, lanes 1–5)
indicated that hBMP2ad represents around 0.02% of total soluble
proteins extracted in the presence of 2-ME.
A more precise quantification of intact zein-hBMP2ad
or released hBMP2ad will be necessary to identify the
best expressor among the different lines. The quantification
should be performed by ELISA technique using anti-hBMP2
antibodies.
DISCUSSION
zein-hBMP2ad Provides Information on the
Requirements for PB Formation
Several studies have reported that the γ-zein N-terminal domain,
can successfully lead to high accumulation via PB formation
FIGURE 9 | The hBMP2 active domain is efficiently released from
zein-hBMP2ad by thrombin cleavage. Twenty-five micrograms of total leaf
proteins, extracted in the presence of 2-ME from zein-hBMP2ad transgenic
(lines #7 and 27) or wt plants, were incubated for 20 h in the presence (+) or
absence (−) of thrombin. The reaction mixtures were analyzed by SDS-PAGE,
followed by protein blot using anti-Flag antiserum. hBMP2ad was quantified by
comparison with known amounts of the commercial standard protein
Flag–BAP (lanes on the left). Empty circles: 20 kD hBMP2ad. Asterisks: 18 kD
fragment of hBMP2ad. Numbers at left indicate the position of the molecular
weight markers, in kDa.
when fused to the N- or C-terminus of other proteins introduced
into the ER, such as bean phaseolin (Mainieri et al., 2004), HIV-
p24 (Virgili-López et al., 2013), xylanase (Llop-Tous et al., 2011),
Moreover, this system can be used not only in plant tissues or
cell cultures but also in fungal, insect, and mammalian cells
(Torrent et al., 2009b). Previous results showed that zeolin, the
chimeric protein obtained by attaching the γ-zein N-terminal
domain at the C-terminus of phaseolin, which is a vacuolar seed
storage protein, has all major features of zein: ER retention,
PB formation and insolubility in absence of reducing agents
(Mainieri et al., 2004). When this γ-zein domain was fused
to the cytosolic viral protein Nef, it was unable to prevent
degradation by the ER quality control (de Virgilio et al., 2008).
However, Nef was stabilized and formed PBs when the entire
zeolin sequence was fused to it. Altogether, these data suggest that
specific structural characteristics of the non-zein portion may
influence the fate of chimeric proteins containing the γ-zein N-
terminal domain. Phaseolin, which like other storage proteins has
a tendency to form large complexes, may contribute to promote
protein packaging accelerating the process of PBs formation.
Conversely, Nef is a cytosolic protein; when introduced into
the oxidizing ER environment its cys residues could negatively
affect correct polymerization by the zein domain, leading to
rapid entry into the degradative pathway of ER quality control
before PB formation could occur. The results presented here
suggest that the seven cysteine residues of hBMP2ad do not
have a destabilizing effect on zein-hBMP2ad and actually the
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chimera accumulates to higher amounts than native hBMP2,
which is a protein naturally introduced into the ER. However
zein-hBMP2ad remains soluble also in the absence of reducing
agents and in large proportion it does not undergo the extensive,
polymerization and insolubilization events that are typical of
protein bodies formed by zein in natural maize seeds and
by zeolin in transgenic plants: velocity gradient centrifugation
showed that most of the chimera forms soluble dimers and
oligomers below 231 kD. This is perhaps an unexpected result,
and constitutes a case in which the zein domain fails to
promote insolubilization but, nevertheless, leads to retention
and stabilization of a protein introduced into the ER. The C-
terminal region of the real 27 kD γ-zein (the 2S albumin-like
domain, Mainieri et al., 2014) contains six cysteines paired in
three intra-chain disulphide bonds. hBMP2ad has one more
cysteine that is engaged in the dimer formation. The position of
this inter-chain disulphide bridge may disturb the close packing
that leads to insolubility. It should also be noticed that we did not
detect secretion of hBMP2nat upon transient expression. This
unexpected result may indicate that anyway, at least in plant cells,
this protein does not efficiently enter intracellular traffic along
the secretory pathway and, in the absence of the zein stabilizing
domain may be degraded by ER quality control.
Subcellular fractionation indicates that zein-hBMP2ad
accumulates in the ER. Its single N-linked glycan can be removed
by endoglycosidase H, indicating that it is not processed by
Golgi-enzymes; itself, this is not a demonstration of lack of
trafficking along the secretory pathway, because protein folding
can inhibit access of Golgi glycosyltransferases, but it is certainly
consistent with an ER localization. Indeed, it has been recently
demonstrated that in CHO cells all the three hBMP2 N-glycans
are EndoH sensitive, even if the protein traffics through the Golgi
complex and is secreted (Hang et al., 2014). The N-glycan of
hBMP2ad might also increase solubility of the chimeric protein,
preventing protein body formation. Phaseolin present in zeolin
also has one N-linked glycan, but this clearly does not impair the
formation of insoluble protein bodies (Mainieri et al., 2004). If
the glycan of hBMP2ad plays a role in preventing insolubility,
one possible explanation for this discrepancy could reside in
the fact that the phaseolin glycan is exposed on the protein
surface, as demonstrated by its accessibility to Golgi enzymes
(Sturm et al., 1987), whereas that of hBMP2ad is probably
masked by interactions with the polypeptide chain, since it does
not become Golgi-modified in vivo. Such different interactions
between N-glycans and the polypeptide chains can exert different
influence on the ability of the chimeric proteins to assemble into
protein bodies.
The question therefore arises of how zein-hBMP2ad is
retained in the ER, in spite of not having a H/KDEL signal for ER
retention and failing to form insoluble large polymers. Pioneering
work on the mechanism of 27 kD γ-zein retention in the ER
showed that the wild-type protein was able to form PB in the
ER of vegetative plant tissues (Shewry et al., 1995), but neither
of the two domains, each corresponding approximately to half
of the protein, could (Geli et al., 1994). The 27 kD γ-zein C-
terminal domain, engineered to enter the ER by the addition
of a signal peptide, was secreted, while the N-terminal domain,
containing its own signal peptide and all the seven cysteine
residues, was soluble also in the absence of reducing agent
and accumulated in the ER as diffuse, slightly electron-dense
material, very different from the well-defined, round shaped
and highly electron dense PB formed by the entire 27 kD γ-
zein polypeptide (Geli et al., 1994). The ER retention of the
N-terminal domain was hypothesized to occur because of the
repeated PPPVHL hexapeptide. It was later shown (Kogan et al.,
2002) that a synthetic version of the eight PPPVHL repeats forms
an amphypatic helix and interacts with liposomes in vitro. It is
therefore possible that the addition of the hBPM2ad sequence
to the zein domain has a sort of “neutral” effect: it does not
alter folding and therefore it does not lead to ER quality control
degradation but at the same time it does not allow extensive
interactions among the Cys residues of the N-terminal zein
domain that are necessary for the formation of the insoluble
PB. Therefore, zein-BMP2ad would behave like the γ-zein N-
terminal domain expressed alone, consistent with the hypothesis
that the structural characteristics of the C-terminal domain of
this prolamin also play a role in PB formation.
Cost-Benefit in Using γ zein-Fusion for the
Production of hBMP2ad in Transgenic
Plants
Actually, rhBMP2 for clinical purpose were produced from
Medtronic in CHO DHFR-deficient cell lines via methotrexate-
mediated gene amplification (Israel et al., 1992). The
consumption of time and the high costs of the purification
steps, added to the low yield of the final product (ng/ml) make
more difficult the widespread use of recombinant rhBMP2
in clinical applications (Lee et al., 2010; Luan et al., 2011).
After the FDA approval, many attempts have been made to
produce rhBMP2 in the less expensive bacterial systems, as an
alternative to mammalian cells (Vallejo et al., 2002; Park et al.,
2014). However, rhBMP2 is a secretory protein that needs the
oxidizing environment of the eukaryotic ER lumen to fold and
assemble correctly; moreover, rhBMP2 produced in E. coli does
not undergo N-glycosylation, a protein modification that occurs
cotranslationally in the ER lumen. Therefore, the biological
activity of E. coli-derived rhBMP2 has to be restored by in vitro
refolding after purification, adding some complexity to the
production method (Kübler et al., 1998; Bessho et al., 2000).
Despite a 110 mg/L production rate of E. coli-derived rhBMP2,
its activity and efficacy after refolding is controversial (Bessho
et al., 2000; Bessa et al., 2008; Yano et al., 2009; Lee et al.,
2010). Recently, same preclinical studies showed promising
results in using E. coli-produced rhBMP2 for the regeneration
of experimentally induced bone defects (Harada et al., 2012;
Ono et al., 2013; Chung et al., 2015; You et al., 2016), even if the
most effective dose as well as the optimal carrier are still to be
determined. A comparison between CHO- and E. coli-derived
rhBMP2 using a dog critical-size supraalveolar peri-implant
model showed that the two rhBMP2s are equally effective
in inducing bone formation (Lee et al., 2013); however, no
economic analysis was provided in this study. Up to now, a
conclusive study on the costs-benefits, based on the comparison
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between the different methods of production of BMP-2 actually
on the market, is not yet available.
In a previous study, Suo et al. (2006) reported the production
of human BMP-2 active domain at level 0.02% TSP in tobacco
plants. It is not easy to make a comparison of this production
efficiency and our results, because the constructs used for tobacco
transformation are different. In Suo et al. (2006), the maximum
yield of hBMP2ad was obtained from plants transformed with
a constructs containing a combination of double 35SCaMV
promoter, AMV enhancer, and two Rb7 MARs sequences that
promotes transgene expression. Plants transformed with the
construct containing a single 35SCaMV promoter, without the
MARS sequences, had about five times lower expression level
(measured by GUS activity). Using a single 35SCaMV promoter,
we reached the yield of about 0.02% TSP, which could be further
improved by doubling the promoter or by addition of enhancer
sequences. It should also be underlined that Suo et al. expressed
hBMP2ad without the signal peptide; the osteogenic factor is
therefore most likely accumulated in the cytosol, a non-optimal
environment for a secretory protein.
A recent randomized clinical trial using E. coli-derived
rhBMP2, reported the efficacy of 0.5–2mg of 1mg/ml rhBMP-
2 in bone formation after maxillary sinus augmentation (Kim
et al., 2015). Obviously, the total dose depends on the defect
size (Boyne et al., 2005; Fiorellini et al., 2005; Herford and
Boyne, 2008; Triplett et al., 2009). Once the initial cost of
the F0 transgenic production has been overcome, plant-based
systems do not require the same expensive investments as
other production methods. From our best producing plant we
recovered about six micrograms of hBMP2ad/g FW: a rough
estimate suggests that one transgenic plant may be sufficient
for a single clinical application. Only a comparative study
between hBMP2 produced in plant, mammalian, or bacterial
systems, will allow to make more precise estimates about cost-
effectiveness, and to establish whether transgenic plants could
really represent a valuable alternative to the currently available
products.
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